Form 8-K - Current report:
SEC Accession No. 0000950170-25-093007
Filing Date
2025-07-02
Accepted
2025-07-02 16:25:20
Documents
10
Period of Report
2025-06-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20250626.htm   iXBRL 8-K 92115
  Complete submission text file 0000950170-25-093007.txt   197086

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250626.xsd EX-101.SCH 23883
12 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250626_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 251101532
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)